Helixon

Helixon, founded in June 2021, is a new drug development enterprise based on advanced artificial intelligence technology. By integrating self-developed high-throughput biological experimental technologies, it provides researchers with an intelligent system for molecular computing, simulation, and design in the microscopic world. In the field of new drug development, especially in large molecule drug development, Helixon will innovatively use AI to reconstruct the drug development process, greatly enhancing the speed and efficiency of new drug research and development. Currently, Helixon possesses revolutionary innovative algorithms for designing various small and large molecule drugs. Its self-developed protein structure prediction algorithm, based on geometric deep learning, has reached world-class precision in predicting three-dimensional protein structures. Moreover, in modeling key regions of antibodies, its accuracy significantly surpasses that of algorithms such as AlphaFold2 and RoseTTAFold.